Understanding the Obstacles to Brain Treatment
The Blood-Brain Barrier
The Blood-Brain Barrier (BBB) is a highly selective, semipermeable membrane protecting the central nervous system. While crucial for allowing essential nutrients like oxygen to pass, it effectively blocks most large molecules and water-soluble compounds, including many life-saving pharma-therapeutics, from reaching the brain. This natural defense mechanism, though vital, significantly limits physicians’ ability to treat Central Nervous System (CNS) and brain cancers. Consequently, treatments are often restricted to invasive direct injectables or implanted pumps, which are frequently ineffective for deep or widespread tumors.
The Mechanics
The Blood-Brain Barrier (BBB) meticulously maintains brain homeostasis by regulating circulatory transport. Endothelial cells, forming tight junctions around brain arteries and capillaries, create a fine mesh that prevents most large molecules from entering. This includes crucial therapeutics like Temozolomide (TMZ), the gold-standard for Glioblastoma Multiforme (GBM). Due to its large and hydrophilic structure, TMZ is blocked by the BBB, preventing it from directly reaching brain tumor tissue and limiting its efficacy.
Additional Barriers
Traditional CNS cancer drug delivery, via IV infusion, oral ingestion, or intrathecal pumps, consistently faces a critical challenge: the Blood-Brain Barrier (BBB). Even direct arterial delivery struggles to achieve sufficient tumor absorption. IV infusion further complicates matters with systemic delivery, causing unwanted side effects and diluting drug concentration in the brain. Oral ingestion adds digestive system travel, further delaying and diminishing therapeutic efficacy. These methods highlight the pressing need for more effective drug transport.
NeOnc has conducted extensive research on its proprietary POH synthesis for various CNS diseases, with a strong focus on Glioblastoma Multiforme (GBM). Through numerous research trials and published studies, our NEO100 and NEO212 formulations have shown a marked beneficial impact. They demonstrate promise both as a standalone therapeutic and as a potent transport mechanism for traditional chemotherapeutics, such as Temozolomide (TMZ), when conjugated.
POH: Enabling Targeted Brain Treatment
The Blood-Brain Barrier (BBB) restricts large or hydrophilic molecules. Only lipophilic, low-molecular-weight molecules with a positive charge can effectively cross. NeOnc’s research confirms that Perillyl Alcohol (POH) possesses these qualities, enabling it to permeate the BBB efficiently.
Beyond permeability, POH, by itself, effectively induces apoptosis (cell growth restriction) in glioblastoma cell lines. Our rigorous animal and human trials show that NEO100, a POH-based formulation, has significantly impacted tumor regression and progression for over three years, markedly improving survivability in both induced and recurrent Glioblastoma Multiforme (GBM). POH’s unique capabilities are transforming targeted brain cancer treatment.
POH: A Universal Delivery Platform
When Perillyl Alcohol (POH) is conjugated with other therapeutics, we believe it significantly enhances a drug’s ability to pass through the Blood-Brain Barrier (BBB) without losing potency. This innovative approach unlocks new possibilities for CNS disease treatment.
A study with Herceptin and NEO100 showed a marked increase in trastuzumab penetration, resulting in brain tumor-selective accumulation of the drug following in vitro and in vivo intravenous delivery, without affecting normal brain tissue.
In another study, intranasal Bortezomib (BZM) combined with NEO100 prolonged survival in tumor-bearing animals, with drug concentrations in the brain notably higher than BZM alone. These findings underscore POH’s powerful capacity as a transport mechanism, amplifying the efficacy of diverse therapeutics for brain-based diseases.